그룹 토론


5월 7일(화)
17:00 - 18:00

Biomarkers for Immunotherapy

Clinical Utility of ctDNA as Predictive IO Marker

Moderator: Helen Rizos, PhD, Head, Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, Australia

Advanced Diagnostics for Infectious Disease

Application of MALDI-TOF MS and Nucleic-Acid Amplification to Microbiological and Virological Diagnosis

Moderator: Adriana Calderaro, MD, PhD, Associate Professor, Clinical Microbiology, Unit of Microbiology and Virology, Department of Medicine and Surgery, University Hospital of Parma, Italy

  • Identification of viruses
  • Identification of bacteria and fungi
  • Identification of parasite

Point-of-Care vs. Central Lab Testing

Moderator: Oliver Liesenfeld, MD, CMO, Inflammatix, United States

  • Point-of-care, point of impact, satellite and central lab
  • What are the clinical requirements/medical needs?
  • What are the assay/instrument requirements?
  • What about data flow, integration into electronic medical records?
  • Who performs the testing?
  • Who is in charge of quality control?

Enabling Technologies for Circulating Biomarkers

How to Survive the in vitro Diagnostic Regulation (Regulation (EU) 2017/746)

Moderator: Michael Messenger, PhD, Head of Personalised Medicine and Health, Leeds Centre for Personalised Medicine and Health, University of Leeds, United Kingdom

  • What is IVDR and how does it differ from the current directive?
  • What are the implications of IVDR on healthcare systems and commercial test developers?
  • What is the community doing to prepare?

Technological Advances for cfDNA and Other Circulating Biomarkers: Challenges and Strategies

Moderator: Jörg Tost, PhD, Director Laboratory for Epigenetics & Environment, Laboratory for Epigenetics & Environment, Centre National de Recherche en Génomique Humaine (CNRGH), CEA – Institut de Biologie Francois Jacob, France

  • What will be the technological platforms for the next generation of circulating biomarker assays?
  • What are key challenges for current assays?
  • Which biomarker to choose for nucleic acid analysis: circulating molecules vs. exosomes?

5월 8일(수)
18:05 - 19:05

Companion Diagnostics for Immuno-Oncology

Open Innovation in Action

Moderator: Pierre Meulien, PhD, Executive Director, Innovative Medicines Initiative, Belgium

  • Extension of open innovation concept to general R&D ecosystem
  • Examples of successes of this principle
  • How open innovation can accelerate implementation of research outcomes in health systems

Point-of-Care Diagnostics

Analyzing Whole Blood Samples in the Point-of-Care

Moderator: Vincent Linder, PhD, Founder and President, CDP BioMedical Consulting, Portugal

  • Unlike centralized laboratory settings where blood cell separation is routinely performed before assaying the samples, Point-of-Care tests are often expected to analyze whole blood samples
  • Should the assay steps include blood cell separation? Or should the device be capable of measuring the analytes in whole blood (without separation)?
  • We will review and discuss advantages and drawbacks of both approaches.
  • The participants will have an opportunity to share their experience and perspective about how either approach greatly impacts the product design/development process.

Complex Diagnostic Systems in a Near Patient Setting

Moderator: Gerd H. Luedke, PhD, Director Innovation, Technology & IP, Curetis GmbH, Germany

  • What is the value of POC diagnostics?
  • What does it need to “look like?”
  • Placement and operators of POC diagnostic systems
  • Antibiotic stewardship: Impact of rapid diagnostics on cost savings for hospitals and isolation of patients with drug resistant pathogens

Clinical Applications of Circulating Biomarkers

Potential of cfDNA as a Point-of-Care Marker in Emergency and Critical Care Settings

Moderator: Andrea Regner, MD, PhD, Professor, Cellular and Molecular Biology Applied to Health, Course of Medicine, Lutheran University of Brazil, Canoas, Brazil

  • Prognosis prediction in acute brain injuries;
  • Defining cutoff of cfDNA that favors high specificity for brain death outcome;
  • Clinical utility of cfDNA quantification in acute medical care scenarios.

Extracellular Vesicles (EVs) as Biomarkers and Mediators of Oncologic Disease

Moderator: Bruno Costa-Silva, PhD, Systems Oncology, Group Leader, Champalimaud Foundation, Portugal

  • Isolation and characterization of EVs
  • Tumour- and Host-derived EVs
  • EVs heterogeneity
  • Emerging technologies for EVs studies

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English



Catalog Download
Catalog



메일링 서비스